BIO-TECHNE Corp
TECHPharma & biotech
Latest available resultsJune 30, 2026Quarter · 10-K filed Aug 24, 2026Report of Nov 3, 2026 spotted, figures not retrieved yet
Next reportFebruary 2, 2027forecast 0.491 $/share
Revenue
$321.19M
▲ +1.3% vs prior year YoY
Net income
$54.62M
▲ +409.0% vs prior year YoY
EPS
—
Net margin
17.0%
▲ +22.6 pp vs prior year YoY
Revenue▲ +1.3%
Margins (% of revenue)GrossOperatingNet
Net income▲ +409.0%
EPS
Financial statements
View 10-K filed August 24, 2026 on SEC ↗| Metric | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025* | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026* | YoY |
|---|---|---|---|---|---|---|---|---|---|
| Operations | |||||||||
| Revenue | $289.46M | $297.03M | $316.18M | $316.96M | $286.56M | $295.88M | $311.42M | $321.19M | ▲ +1.3% |
| Gross profit | $183.02M | $193.89M | $214.56M | $198.81M | $188.11M | $191.28M | $208.29M | $211.39M | ▲ +6.3% |
| Operating income | $39.99M | $47.42M | $38.71M | −$23.86M | $47.66M | $54.46M | $75.50M | $74.28M | ▲ +411.3% |
| Net income | $33.60M | $34.89M | $22.59M | −$17.68M | $38.19M | $38.01M | $51.05M | $54.62M | ▲ +409.0% |
| R&Dnever filed | — | — | — | — | — | — | — | — | — |
| EPS (diluted) | 0.21 $ | 0.22 $ | 0.14 $ | — | 0.24 $ | 0.24 $ | 0.32 $ | — | — |
| Margins (% of revenue) | |||||||||
| Gross | 63.2 % | 65.3 % | 67.9 % | 62.7 % | 65.6 % | 64.6 % | 66.9 % | 65.8 % | ▲ +3.1 pt |
| Operating | 13.8 % | 16.0 % | 12.2 % | -7.5 % | 16.6 % | 18.4 % | 24.2 % | 23.1 % | ▲ +30.7 pt |
| Net | 11.6 % | 11.7 % | 7.1 % | -5.6 % | 13.3 % | 12.8 % | 16.4 % | 17.0 % | ▲ +22.6 pt |
| Balance sheet | |||||||||
| Assets | $2.74B | $2.67B | $2.64B | $2.56B | $2.53B | $2.52B | $2.55B | $2.59B | ▲ +1.1% |
| Liabilities | $597.37M | $591.93M | $626.23M | $639.06M | $560.33M | $511.71M | $465.30M | $478.50M | ▼ -25.1% |
| Equity | $2.14B | $2.08B | $2.02B | $1.92B | $1.97B | $2.01B | $2.09B | $2.11B | ▲ +9.9% |
| Cash | $187.54M | $177.55M | $140.67M | $162.19M | $144.96M | $172.88M | $209.82M | $264.71M | ▲ +63.2% |
| Capital | |||||||||
| Shares outstanding | 158.89M | 158.09M | 156.77M | 155.55M | 155.81M | 156.45M | 156.57M | 157.06M | ▲ +1.0% |
| Public floatexcluding insiders | — | — | — | — | — | — | — | — | — |
* No 10-Q is filed for a fourth quarter: these amounts are the fiscal year minus the first three quarters, all filed. EPS stays blank — dilution doesn't subtract.